Clinical laboratory services market seen topping $418B by 2030

The Business Research Company projects the global clinical laboratory services market will reach $418.25 billion by 2030, driven by chronic and infectious disease testing, early diagnosis demand and personalized care. North America and the U.S. are expected to lead growth, while medical microbiology testing remains the biggest segment.

Why it matters: - The clinical laboratory services market is projected to exceed $418 billion by 2030, making it a meaningful slice of the wider healthcare services market. - The market is forecast to account for nearly 4% of the estimated $11.335 trillion healthcare services industry in 2030. - Growth in laboratory testing affects diagnosis speed, disease monitoring and care decisions across hospitals, clinics and independent labs.

What happened: - The Business Research Company released a 2026 market forecast for clinical laboratory services. - The report estimates the global market at $418.25 billion by 2030. - The market is projected to grow at a 6% CAGR through 2030. - Request a free sample of the report. - Access the full market report.

The details: - North America is expected to be the largest region in 2030, with a market value of $185 billion. - North America’s market is projected to rise from $145 billion in 2025 at a 5% CAGR. - The U.S. is forecast to be the largest country market in 2030 at $169 billion. - The U.S. market is projected to grow from $133 billion in 2025 at a 5% CAGR. - The biggest drivers in North America include chronic and infectious disease prevalence, demand for early and accurate testing, outpatient care expansion, decentralized care, advanced diagnostic assays, molecular testing, EHR-LIS integration, and stronger quality standards. - In the U.S., growth is tied to preventive screening, specialized oncology and genetic testing, hospital and independent lab expansion, automation, high-throughput platforms, precision medicine investment and stronger compliance frameworks. - By test type, medical microbiology testing is expected to be the largest segment in 2030 at 29% of the market, or $120 billion. - The report segments the market by service type into hospital-based laboratories, stand-alone laboratories and clinic-based laboratories. - The report segments the market by technology into conventional laboratory technology, automated laboratory technology and point-of-care testing. - The report segments the market by application into bioanalytical and lab chemistry services, toxicology testing services, cell and gene therapy related services, preclinical and clinical trial related services, drug discovery and development related services, and other clinical laboratory services. - The report segments the market by end user into hospitals, diagnostic laboratories, clinics and research institutions. - The report says medical microbiology testing is supported by infectious disease prevalence, antimicrobial resistance concerns, rapid pathogen identification needs, infection control programs, automated culture and molecular diagnostics, outbreak detection investment and faster turnaround times. - The biggest growth opportunities through 2030 are expected in genetic testing, clinical chemistry, medical microbiology testing, hematology testing, immunology testing, cytology testing, drug of abuse testing and other test types. - Those segments are projected to contribute more than $105 billion in market value by 2030. - The genetic testing market is projected to add $6 billion from 2025 to 2030. - The clinical chemistry market is projected to add $7 billion. - The medical microbiology testing market is projected to add $30 billion. - The hematology testing market is projected to add $16 billion. - The immunology testing market is projected to add $4 billion. - The cytology testing market is projected to add $5 billion. - The drug of abuse testing market is projected to add $26 billion. - The other test types market is projected to add $11 billion.

Between the lines: - The forecast points to steady demand rather than a single disruptive catalyst. - The market’s center of gravity appears to be shifting toward faster, more automated and more specialized testing. - The strongest gains are concentrated in microbiology and drug of abuse testing, which suggests both infectious disease surveillance and broader screening demand are expanding. - The report’s emphasis on preventive care and precision medicine suggests diagnostics are becoming more embedded in routine healthcare delivery.

What's next: - Lab operators, diagnostic firms and investors will likely focus on automation, molecular testing, and data integration to capture growth. - Regional leaders in North America and the U.S. may continue to benefit from chronic disease burden and higher testing adoption. - Demand for microbiology, genetic and chemistry testing is likely to remain central through 2030.

The bottom line: - Clinical laboratory services are set for broad-based growth through 2030, with the fastest gains expected in testing that supports early diagnosis, infection control and precision medicine.